Immuneering Corporation (NASDAQ:IMRX) Given Average Rating of “Moderate Buy” by Analysts

Shares of Immuneering Corporation (NASDAQ:IMRX) have been given a consensus recommendation of “Moderate Buy” by the seven analysts that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, five have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $16.50.

A number of equities analysts have recently commented on the stock. Wall Street Zen upgraded shares of Immuneering from a “sell” rating to a “hold” rating in a research note on Sunday, April 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immuneering in a research note on Friday, March 27th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $11.00 target price on shares of Immuneering in a research note on Monday, March 9th.

Institutional Trading of Immuneering

Several large investors have recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd acquired a new stake in Immuneering in the fourth quarter valued at approximately $33,000. China Universal Asset Management Co. Ltd. acquired a new position in Immuneering during the 3rd quarter worth about $35,000. Future Financial Wealth Managment LLC acquired a new position in Immuneering during the 3rd quarter worth about $35,000. Mercer Global Advisors Inc. ADV acquired a new position in Immuneering during the 3rd quarter worth about $70,000. Finally, SummitTX Capital L.P. acquired a new position in Immuneering in the fourth quarter valued at $69,000. Institutional investors and hedge funds own 67.65% of the company’s stock.

Immuneering Stock Performance

Shares of Immuneering stock opened at $6.13 on Friday. The firm has a fifty day moving average of $5.27 and a two-hundred day moving average of $5.76. The stock has a market capitalization of $396.61 million, a price-to-earnings ratio of -4.44 and a beta of 0.43. Immuneering has a 52 week low of $1.10 and a 52 week high of $10.08.

Immuneering (NASDAQ:IMRX) last released its quarterly earnings data on Friday, March 6th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.13. As a group, research analysts forecast that Immuneering will post -1.42 EPS for the current fiscal year.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.